Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae: Risk Factors and Economic Burden Among Patients with Bloodstream Infections
Jiakang Chen,Kasim Allel,Chuyue Zhuo,Wenwei Luo,Nanhao He,Xu Yang,Yingyi Guo,Jiong Wang,Likang Yao,Jiahui Li,Yexin Lin,Ruiyang Tu,Laith Yakob,Chao Zhuo
DOI: https://doi.org/10.2147/rmhp.s453686
2024-02-29
Risk Management and Healthcare Policy
Abstract:Jiakang Chen, 1, &ast Kasim Allel, 2– 4, &ast Chuyue Zhuo, 1, &ast Wenwei Luo, 5 Nanhao He, 1 Xu Yang, 1 Yingyi Guo, 1 Jiong Wang, 1 Likang Yao, 1 Jiahui Li, 1 Yexin Lin, 1 Ruiyang Tu, 6 Laith Yakob, 2, 3 Chao Zhuo 1 1 State Key Laboratory of Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, People's Republic of China; 2 Department of Disease Control, Faculty of Infectious & Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK; 3 Antimicrobial Resistance Centre, London School of Hygiene & Tropical Medicine, London, UK; 4 Institute for Global Health, University College London, London, UK; 5 Department of Clinical Laboratory, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, People's Republic of China; 6 Department of Science and Technology Studies, University College London, London, UK &astThese authors contributed equally to this work Correspondence: Chao Zhuo, State Key Laboratory of Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, 151 Yanjiang Road, Guangzhou, Guangdong, People's Republic of China, Email Introduction: Although Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae (ESBL-EK) significantly contribute to bloodstream infections, their economic repercussions remain largely unquantified. Data Source and Methods: We performed a retrospective analysis of inpatients diagnosed with Escherichia coli or Klebsiella pneumoniae bacteremia in a tertiary hospital from January 2020 to December 2022 in Guangzhou, China. We employed the chi-square test to examine ESBL risk factors and utilized propensity score matching (PSM) to negate baseline confounding factors, assessing economic burden through disability-adjusted life years (DALYs), hospital costs and productivity losses. We employed mediation analysis to eliminate confounding factors and better identify ESBL sources of burden related. Results: We found 166 ESBL-EC/KP BSI patients (52.2% of the total examined 318 patients). Post-PSM analysis revealed that ESBL-producing EC/KP will reduce the effectiveness of empirical medication by 19.8%, extend the total length of hospitalization by an average of 3 days, and increase the patient's financial burden by US&dollar2047. No significant disparity was found in overall mortality and mean DALYs between the groups. Mediation analysis showed that the link between ESBL and hospital costs is predominantly, if not entirely, influenced by the appropriateness of empirical antibiotic treatment and length of hospital stay. Conclusion: Patients with BSI due to ESBL-producing ESBL-EK incur higher costs compared to those with non-ESBL-EK BSI. This cost disparity is rooted in varying rates of effective empirical antimicrobial therapy and differences in hospital stay durations. A nuanced approach, incorporating a thorough understanding of regional epidemiological trends and judicious antibiotic use, is crucial for mitigating the financial impact on patients. Keywords: Escherichia coli , Klebsiella pneumoniae , bacteremia, ESBL, risk factors, medical costs Bloodstream infections (BSI) rank among the most prevalent and severe bacterial challenges in clinical medicine, significantly contributing to global disease burden. 1–3 A European study estimated over 160,000 healthcare-associated (HA) primary BSIs in the European Union and the European Economic Area (EU/EEA) per year, leading to more than 24,000 fatalities. 4,5 This burden is surpassed only by hospital-acquired pneumonia (HAP) among HA infections, presenting a formidable public health crisis. Furthermore, in 2019, antimicrobial resistance (AMR) was a complicating factor in approximately 1,500,000 BSI-related deaths worldwide, severely limiting treatment options and escalating the healthcare challenge. 2 Klebsiella pneumoniae (KP) and Escherichia coli (EC) stand out as leading pathogens in bloodstream infections (BSI), with their global prevalence escalating notably in the past decade. 3,5 In China, EC and KP are found in 35% of blood samples, with elevated presence of resistance mechanisms, including ESBL carrying rates (surpassing 40% among isolates). 6 A Guangdong Province study highlighted that over 40% of pediatric EC and KP isolates are ESBL-producers, hinting at possibly higher current rates. 7 ESBL genes, predominantly ho -Abstract Truncated-
health care sciences & services,health policy & services